Kazia Therapeutics (KZIA) Equity Average (2009 - 2024)

Kazia Therapeutics (KZIA) has 13 years of Equity Average data on file, last reported at -$1.6 million in Q2 2024.

• In Q2 2024, Equity Average fell 120.25% year-over-year to -$1.6 million; the TTM figure through Jun 2024 stood at -$1.6 million (down 120.25% YoY), while the FY2025 annual figure was -$6.0 million, down 920.61% from the prior year.
• Equity Average fell to -$1.6 million in Q2 2024, from $5.7 million in the prior quarter.
• Across five years, Equity Average topped out at $26.2 million in Q2 2021 and bottomed at -$1.6 million in Q2 2024.
• A 5-year average of $11.8 million and a median of $9.6 million in 2020 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2021 — Equity Average surged 196.65% — and 2024, when it tumbled 120.25%.
• Year by year, Equity Average stood at $16.2 million in 2020, then soared by 61.36% to $26.2 million in 2021, then slumped by 60.42% to $10.3 million in 2022, then plunged by 44.53% to $5.7 million in 2023, then slumped by 127.63% to -$1.6 million in 2024.
• The last three Equity Average figures came in at -$1.6 million (Q2 2024), $5.7 million (Q4 2023), and $7.8 million (Q2 2023), per Business Quant data.

Peer Comparison